Press Room

DDL 2021

Start
Wednesday, December 08, 2021 - 00:00
End
Friday, December 10, 2021 - 00:00
Location: Online

ɫAV scientist at DDL Conference Nasal PAMPA intranasal drug permeability | ɫAV

Presenter: Patrícia Henriques, PhD Student, R&D DPD

Abstract:
In nasal drug product development, biorelevantin vitromethodologies are vital in order to select promising compounds or formulations, potentially reducing pre-clinical and clinical trials. Permeability assays are often applied to predict drug absorption and bioavailability. For nasal delivery products, permeation models includeex vivomodels using excised nasal mucosa andin vitrocell culture models. However,ex vivomodels present high variability and cell culture models are very time consuming. The Parallel Artificial Membrane Permeability Assay (PAMPA) has emerged as a high throughput screening tool to evaluate drug permeability, and it has been applied to several barriers such as the intestine, skin or blood-brain-barrier. Herein, a new PAMPA model was developed and optimized to predict nasal permeability, using a biorelevant donor medium containing mucin. The apparent permeability (Papp) of 15 reference compounds was assessed in six different experimental conditions. The model with 0.5% (w/v) mucin in the donor compartment and 2% (w/v) phosphatidylcholine in the lipid membrane correctly distinguished high and low permeable compounds, with no false positives or negatives. In addition, it exhibited the highest correlation with permeation across human nasal epithelial RPMI 2650 cells (R2= 0.71). Overall, the optimized PAMPA model was reproducible, predictive and inexpensive, showing to be a promising non-cell based and biorelevantin vitrotool that could be applied in an early screening stages of new nasal drug delivery products.

ɫAV scientist at DDL Conference DPI formulation screening: particle-particle interaction | ɫAV
ɫAV scientist Joao Pereira at DDL Conference DPI formulation screening: particle-particle interaction | ɫAV

Presenters:
Raquel Borda D’Água, Associate Analytical Scientist, R&D Analytical Development
João Pereira, Manager R&D Analytical Development

Abstract:
Dry powder inhalers (DPIs) have attracted enormous attention worldwide due to its local targeting, rapid drug effect and reduced systemic toxicity. However, DPI formulations consist of highly cohesive powders that tend to agglomerate. Therefore, understanding the role of cohesive-adhesive forces in different formulations and establishing a predictive approach for aerodynamic particle size distribution (aPSD) is thus, highly beneficial. The purpose of this study is to explore the relationship between powder dispersibility with the aerodynamic performance of different DPI formulations. Sympatec was used to characterise powder dispersibility and inherent cohesion and adhesion forces at different pressures. Powder dispersibility obtained by Sympatec and aerodynamic properties from the NGI analysis were evaluated in order to deeper understand the characteristic behaviour of these formulations

Take advantage of cutting-edge particle engineering technologies highly skilled responsive staff and state of the art analytical facilities.


Everything for Inhalation

Inhalation high performance APIs particle engineering formulation DPIs pdf | ɫAV



Also in the Press Room

See All

Lisbon, Portugal – ɫAV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, ɫAV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At ɫAV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of ɫAV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” ɫAV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with ɫAV’s sustainability ambitions.  ɫAV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

ɫAV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024